ARDELYX, INC. Accrued Liabilities, Current
ARDELYX, INC. (ARDX) had Accrued Liabilities, Current of $12.86 million as of 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2019-03-06
- 2018-12-31: Accrued Liabilities, Current $12.86M.
- 2017-12-31: Accrued Liabilities, Current $10.71M.
- 2016-12-31: Accrued Liabilities, Current $10.40M.
- 2015-12-31: Accrued Liabilities, Current $1.33M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2018-12-31 | $12.86M 10-K · filed 2019-03-06 |
| 2017-12-31 | $10.71M 10-K · filed 2019-03-06 |
| 2016-12-31 | $10.40M 10-K · filed 2018-03-14 |
| 2015-12-31 | $1.33M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |